Veracyte appoints Tina Nova as President of CLIA U.S. business

VERACYTE, INC.

Tina S. Nova, Ph.D., appointed President of Veracyte's CLIA U.S. business effective January 6, 2022.
Dr. Nova previously served as General Manager, Thyroid and Urologic Cancers since March 2021.
She was on Veracyte's board from Nov 2015 to Feb 2021 and was CEO of Decipher before its acquisition.
Dr. Nova will enter into standard indemnification agreement; no family relationships or material transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tina S. Nova, Ph.D.

President of the Company’s CLIA U.S. business

VCYT · VERACYTE, INC.

Effective: 2022-01-06
Filed: January 11, 2022, 6:59 PM ET

On January 6, 2022, Veracyte, Inc. (the “Company”), announced certain key leadership promotions including the appointment of Tina S. Nova, Ph.D., to serve as President of the Company’s CLIA U.S. business, effective as of January 6, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tina S. Nova, Ph.D. was appointed as President of the Company’s CLIA U.S. business at VERACYTE, INC..

Action: appointed
Role: President of the Company’s CLIA U.S. business

Exact text from the filing

On January 6, 2022, Veracyte, Inc. (the “Company”), announced certain key leadership promotions including the appointment of Tina S. Nova, Ph.D., to serve as President of the Company’s CLIA U.S. business, effective as of January 6, 2022.

View on SEC.gov

VERACYTE, INC. filing history →

Source: SEC EDGAR

accession 0001384101-22-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.